{
    "pmcid": "8646660",
    "qa_pairs": {
        "How does the FD20 antibody neutralize the SARS-CoV-2 virus?": [
            "By destructing the spike protein",
            "By blocking ACE2 binding",
            "By inhibiting viral replication",
            "By preventing viral assembly"
        ],
        "What is the primary target of the monoclonal antibody FD20 on the SARS-CoV-2 spike protein?": [
            "A conserved epitope on the RBD, distal to the RBM",
            "The receptor-binding motif (RBM) on the RBD",
            "The S2 subunit of the spike protein",
            "The N-terminal domain of the S1 subunit"
        ],
        "What is the significance of the conserved epitope targeted by FD20 in terms of mutation?": [
            "It suggests structural and functional constraints that limit mutation, reducing the likelihood of escape mutants",
            "It is highly mutable, leading to frequent escape mutations",
            "It is only conserved in the original SARS-CoV-2 strain",
            "It is conserved but allows for significant functional mutations"
        ],
        "What potential application does the study suggest for FD20 in therapeutic development?": [
            "Use in antibody cocktails with other non-competing mAbs to enhance efficacy and prevent viral escape",
            "Development as a standalone vaccine",
            "Use as a diagnostic tool for SARS-CoV-2 detection",
            "Incorporation into antiviral drugs targeting viral replication"
        ],
        "Which SARS-CoV-2 variants does FD20 effectively neutralize without significant loss of potency?": [
            "Alpha, Beta, Gamma, and Delta",
            "Omicron, Lambda, Mu, and Epsilon",
            "Zeta, Eta, Iota, and Kappa",
            "Theta, Nu, Xi, and Pi"
        ]
    }
}